---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-218175"
form_type: "8-K"
ticker: "ACHV"
cik: "0000949858"
company_name: "ACHIEVE LIFE SCIENCES, INC."
filed_at: "2026-05-12T11:20:21+00:00"
generated_at: "2026-05-12T11:25:20.035023+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Q1 cash $29.3M; closed $180M upfront financing; expects CRL by June 20, 2026; new CEO appointed

## Summary
- Q1 cash, equivalents, and marketable securities $29.3M; net loss $10.2M, operating expenses $10.5M.
- Closed private placement of up to $354M ($180M upfront + $174M milestone warrants).
- Andrew D. Goldberg, MD appointed CEO and board member; Christopher Martin added as director.
- Expects CRL from FDA by June 20, 2026; to resubmit NDA in Q4 2026 with new manufacturer Adare.
- Jaime Xinos departs as CCO May 31; Lucian Iancovici becomes Chair; Tom King steps down June 8.

## SEC filing metadata
- accession: 0001193125-26-218175
- form_type: 8-K
- ticker: ACHV
- cik: 0000949858
- company_name: ACHIEVE LIFE SCIENCES, INC.
- filed_at: 2026-05-12T11:20:21+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/949858/000119312526218175/0001193125-26-218175-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/949858/000119312526218175/d854692d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-218175
- JSON: https://secwatch.observer/filing/0001193125-26-218175.json
- Plain text: https://secwatch.observer/filing/0001193125-26-218175.txt

## Key facts
- Earnings Releases
  ACHIEVE LIFE SCIENCES, INC. reported financial results for the first quarter of 2026.
  - Period: the first quarter of 2026
  - Result: reported results
  source text: today announced financial results for the first quarter of 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/949858/000119312526218175/0001193125-26-218175-index.htm
- Earnings Releases
  ACHIEVE LIFE SCIENCES, INC. reported financial results for the first quarter ended March 31, 2026.
  - Period: the first quarter ended March 31, 2026
  - Result: reported results
  source text: On May 12, 2026, Achieve Life Sciences, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/949858/000119312526218175/0001193125-26-218175-index.htm
- Earnings Releases
  ACHIEVE LIFE SCIENCES, INC. reported the three months ended March 31, 2026 results: net income $10.2 million.
  - Period: the three months ended March 31, 2026
  - Net income: $10.2 million
  - Result: reported results
  source text: Total operating expenses and net loss for the three months ended March 31, 2026 were $10.5 million and $10.2 million, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/949858/000119312526218175/0001193125-26-218175-index.htm
- Executive change
  Thomas King resigned as Chairman of the Board and Member at ACHIEVE LIFE SCIENCES, INC..
  - Action: resigned
  - Role: Chairman of the Board and Member
  source text: Thomas King informed the Board that he has elected to resign from his position as a member and as chairman of the Board, effective as of June 8, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/949858/000119312526218175/0001193125-26-218175-index.htm
- Executive change
  Jaime Xinos departed as Chief Commercial Officer at ACHIEVE LIFE SCIENCES, INC..
  - Action: departed
  - Role: Chief Commercial Officer
  source text: Jaime Xinos, the Company’s Chief Commercial Officer, will depart the Company, effective as of May 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/949858/000119312526218175/0001193125-26-218175-index.htm
- Executive change
  Lucian Iancovici was appointed as Chair of the Board at ACHIEVE LIFE SCIENCES, INC..
  - Action: appointed
  - Role: Chair of the Board
  source text: Lucian Iancovici, MD, was appointed as Chair of the Board, effective as of June 8, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/949858/000119312526218175/0001193125-26-218175-index.htm
- Executive change
  Christopher Martin was appointed as Director at ACHIEVE LIFE SCIENCES, INC..
  - Action: appointed
  - Role: Director
  source text: appointed Christopher Martin to serve as a director of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/949858/000119312526218175/0001193125-26-218175-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.